Cancer immunotherapy target helps fight solid tumors

February 15, 2020

SAN DIEGO, CA - Yvonne Chen engineers immune cells to target their most evasive enemy: cancer. New cancer immunotherapies generate immune cells that are effective killers of blood cancers, but they have a hard time with solid tumors. Chen, Associate Professor at the University of California, Los Angeles (UCLA) and a member of the Jonsson Comprehensive Cancer Center, is designing ways for immune cells to "outsmart" solid tumors. She will present her research on Tuesday, February 18, at the 64th Annual Meeting of the Biophysical Society in San Diego, California.

T cells, which are a type of white blood cells, patrol and attack invaders to our bodies, but they also need to avoid assault on our own cells, which is one of the ways cancers are able to "hide" from the immune system. Solid tumors, cancers that form a mass in the body, make up 90% of cancer cases and can even inactivate immune cells. These tumors can surround themselves in a protein called transforming growth factor beta (TGF?β), which suppresses the activity of T cells in the tumor environment. Chen found a way to help T cells turn TGF?β back on tumor cells.

T cells can be engineered to produce receptors known as chimeric antigen receptors (CARs), which are designed to recognize tumor-associated proteins known as antigens. Upon encountering cells that present the target antigen, CAR-T cells can latch onto the target cell and kill it. T cells engineered to express CARs that target CD19, an antigen found on B cells, have been approved by the FDA for the treatment of B-cell leukemia and lymphoma.

Although CD19 CAR-T cell therapy has shown promising clinical results, sometimes through the course of treatment, a population of cancer cells without CD19 emerge. "Clinical trials have shown that 50% of lymphoma patients treated with CD19 CAR-T cell therapy would relapse within 6 months, and many of those cases involve tumor cells that no longer express CD19," Chen said. To circumvent this, Chen engineered T cells that target both CD19 and CD20, reducing the possibility that any cancer cells will evade treatment. This bispecific CAR-T cell therapy is now being tested in a phase-1 clinical trial at UCLA.

In addition to blood cancers, solid tumors have been the focus of much ongoing research activity in the Chen Lab. "Immunotherapy works well against blood tumors, but hasn't worked as well against solid tumors, in part because of TGF?β-induced immunosuppression," Chen said. Her new approach with a CAR engineered against TGF?β is a promising start targeting solid tumors. "TGF?β CAR has shown the potential to safely and effectively boost the anti?tumor efficacy of T?cell therapy."

Chen and colleagues made CARs that respond to TGF?β by ramping up their defenses. "Instead of responding to TGF?β by shutting down, T cells that express the TGF-β-responsive CAR would be geared up to encounter and attack a tumor cell when exposed to high concentrations of TGF-β," Chen said. Chen and colleagues are developing TGF-β CAR-T cells that also target another tumor-specific marker, in order to develop a next-generation T cell therapy that can effectively combat immunosuppressive solid tumors.
-end-


Biophysical Society

Related Cancer Cells Articles from Brightsurf:

Cancer researchers train white blood cells to attacks tumor cells
Scientists at the National Center for Tumor Diseases Dresden (NCT/UCC) and Dresden University Medicine, together with an international team of researchers, were able to demonstrate that certain white blood cells, so-called neutrophil granulocytes, can potentially - after completing a special training program -- be utilized for the treatment of tumors.

New way to target some rapidly dividing cancer cells, leaving healthy cells unharmed
Scientists at Johns Hopkins Medicine and the University of Oxford say they have found a new way to kill some multiplying human breast cancer cells by selectively attacking the core of their cell division machinery.

Breast cancer cells use message-carrying vesicles to send oncogenic stimuli to normal cells
According to a Wistar study, breast cancer cells starved for oxygen send out messages that induce oncogenic changes in surrounding normal epithelial cells.

Breast cancer cells turn killer immune cells into allies
Researchers at Johns Hopkins University School of Medicine have discovered that breast cancer cells can alter the function of immune cells known as Natural killer (NK) cells so that instead of killing the cancer cells, they facilitate their spread to other parts of the body.

Breast cancer cells can reprogram immune cells to assist in metastasis
Johns Hopkins Kimmel Cancer Center investigators report they have uncovered a new mechanism by which invasive breast cancer cells evade the immune system to metastasize, or spread, to other areas of the body.

Engineered immune cells recognize, attack human and mouse solid-tumor cancer cells
CAR-T therapy has been used successfully in patients with blood cancers such as lymphoma and leukemia.

Drug that keeps surface receptors on cancer cells makes them more visible to immune cells
A drug that is already clinically available for the treatment of nausea and psychosis, called prochlorperazine (PCZ), inhibits the internalization of receptors on the surface of tumor cells, thereby increasing the ability of anticancer antibodies to bind to the receptors and mount more effective immune responses.

Engineered bone marrow cells slow growth of prostate and pancreatic cancer cells
In experiments with mice, researchers at the Johns Hopkins Kimmel Cancer Center say they have slowed the growth of transplanted human prostate and pancreatic cancer cells by introducing bone marrow cells with a specific gene deletion to induce a novel immune response.

First phase i clinical trial of CRISPR-edited cells for cancer shows cells safe and durable
Following the first US test of CRISPR gene editing in patients with advanced cancer, researchers report these patients experienced no negative side effects and that the engineered T cells persisted in their bodies -- for months.

Zika virus' key into brain cells ID'd, leveraged to block infection and kill cancer cells
Two different UC San Diego research teams identified the same molecule -- αvβ5 integrin -- as Zika virus' key to brain cell entry.

Read More: Cancer Cells News and Cancer Cells Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.